login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
RHYTHM PHARMACEUTICALS INC (RYTM) Stock News
USA
-
Nasdaq
- NASDAQ:RYTM -
US76243J1051
-
Common Stock
104.6
USD
-1.1 (-1.04%)
Last: 12/5/2025, 8:00:01 PM
104.6
USD
0 (0%)
After Hours:
12/5/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RYTM Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
a month ago - By: The Motley Fool
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million
a month ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
a month ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
a month ago - By: Benzinga
- Mentions:
KURA
SEE
HRMY
FOLD
...
Earnings Scheduled For November 4, 2025
a month ago - By: Benzinga
Rhythm Pharmaceuticals's Earnings: A Preview
a month ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
a month ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
a month ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
a month ago - By: Zacks Investment Research
- Mentions:
IFRX
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
a month ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
a month ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
a month ago - By: Zacks Investment Research
- Mentions:
RPRX
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
5 months ago - By: The Motley Fool
- Mentions:
LLY
Should You Invest in This Under-the-Radar Weight Loss Stock?
2 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
2 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
3 months ago - By: Yahoo Finance
- Mentions:
MS
FDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM)
3 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
3 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
4 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
4 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
4 months ago - By: Zacks Investment Research
- Mentions:
ROIV
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
4 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
4 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
4 months ago - By: Yahoo Finance
Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)
4 months ago - By: Zacks Investment Research
- Mentions:
PRTA
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
5 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
5 months ago - By: Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
Please enable JavaScript to continue using this application.